💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Levodopa

CHEMBL1009 Phase 4 अनुमोदित Small molecule
Half-Life
1.5 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
197.2 g/mol
LogP
-2.7
Phase
4

Levodopa is a metabolic precursor of dopamine and the primary treatment for Parkinson's disease. Unlike dopamine itself, it crosses the blood-brain barrier, where it is converted to the neurotransmitter to replace what is lost as the disease progresses. It is almost always combined with carbidopa, which prevents its breakdown outside the brain and reduces side effects. The amino-acid derivative has the formula C9H11NO4 and is marketed in combinations such as Carbidopa-Levodopa and Duopa.

A dopamine precursor used as the primary treatment for Parkinson's disease, where it is converted to dopamine in the brain to replace the lost chemical messenger. It is typically combined with carbidopa to enhance its effectiveness and reduce side effects.

आणविक भार

197.1880 g/mol

LogP

-2.70

TPSA

104.00 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

न्यूरोलॉजी (तंत्रिका विज्ञान) पार्किंसन रोग

दवा वर्ग

N — N - तंत्रिका तंत्र

क्रिया का तंत्र

Metabolic precursor of dopamine that crosses the BBB.

Pharmacokinetics (PK)

Half-Life 1.5 hours

Pharmacodynamics (PD)

तंत्र

Metabolic precursor of dopamine that crosses the BBB.

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C9H11NO4

                    

                    
                    

                        
HBD / HBA

                        
4 / 5

                    

                    
                    

                        
घूर्णनीय बंधन

                        
3

                    

                    
                    
                    

                        
भारी परमाणु

                        
14

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Levodopa + Quetiapine
                            
                        

                        
                        
Quetiapine, a D2 receptor antagonist, pharmacodynamically opposes levodopa's dopaminergic effect, worsening Parkinson's disease motor symptoms.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Levodopa + Aripiprazole
                            
                        

                        
                        
Aripiprazole acts as a partial D2 agonist/antagonist and can oppose levodopa's dopaminergic therapy, worsening Parkinson's disease symptoms.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Levodopa + Carbamazepine
                            
                        

                        
                        
Carbamazepine may reduce levodopa efficacy through enzyme induction and pharmacodynamic antagonism, potentially worsening Parkinson's disease control.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
A dopamine precursor used as the primary treatment for Parkinson's disease, where it is converted to dopamine in the brain to replace the lost chemical messenger. It is typically combined with carbidopa to enhance its effectiveness and reduce side effects.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Metabolic precursor of dopamine that crosses the BBB.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Levodopa: Half-life: 1.5 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Levodopa is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1009.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6047.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.